Advertisement


Danny Rischin, MD, on Adjuvant Cemiplimab for High-Risk CSCC

ASCO 2026

Advertisement

Danny Rischin, MD, of Peter MacCallum Cancer Centre, talks about data from the disease-free survival analyses of the C-POST study, which were conducted per high-risk criteria and start time after radiotherapy. C-POST evaluated adjuvant cemiplimab-rwlc for patients with high-risk cutaneous squamous cell carcinoma (CSCC) (Abstract 6083).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The C-POST trial is a phase 3 trial in patients with high-risk cutaneous squamous cell carcinoma. They compared adjuvant cemiplimab with placebo. In this trial, patients who had high-risk cutaneous SCC were randomized to either receive cemiplimab for 48 weeks or placebo. These patients had to have had surgery with complete macroscopic resection and have completed radiotherapy. This was a positive trial with clinically meaningful and statistically significant results: a hazard ratio of 0.32 and a P value of less than .001. So, a 68% reduction in the risk of disease recurrence or death, and this included a decrease in risk of locoregional recurrence and distant recurrences. At this ASCO meeting, we presented further analysis to better understand the benefits of cemiplimab as an adjuvant treatment in this population. In the C-POST trial, patients were selected based on high-risk criteria. These high-risk criteria could be nodal, such as having a lymph node that was greater than 2 cm with extranodal extension or more than 3 nodes, or several high-risk nonnodal criteria, such as in-transit metastases, T4 disease, perineural invasion, if there was involvement clinically or radiologically, or recurrent disease with other high-risk features. So what we wanted to see in these further analyses is whether all of these groups conveyed a disease-free benefit with cemiplimab compared with placebo. So we looked at all of these nodal and nonnodal criteria, and in fact, in every single group, there was similar disease-free benefit with cemiplimab versus placebo. The other thing that we looked at was the interval between completion of radiation and randomization. The protocol stipulated that patients had to start treatment or at least be randomized between 2 and 11 weeks after completing their radiotherapy. The median was 5.6 weeks. So we looked at the group that started within 2 to 6 weeks and the group that started in 6 to 11 weeks. And in fact, there was a similar disease-free benefit, irrespective of the interval since radiation. These analyses were conducted with updated follow-up, with a median follow-up of 30 months, and the overall disease-free benefit is still significant at 0.335. These results further reinforce that this benefit from adjuvant cemiplimab was seen in all the high-risk groups and irrespective of the interval from radiation. Further follow-up is ongoing of the C-POST trial, and longer-term follow-up and survival analysis will be presented at a later date.

Related Videos

Breast Cancer
Genomics/Genetics

Wassim McHayleh, MD, FACP, MBA, on Elacestrant Plus Capivasertib in ER-Positive/HER2-Negative Advanced Breast Cancer: Update From ELEVATE

Wassim McHayleh, MD, FACP, MBA, of AdventHealth Cancer Institute, provides an update from the phase Ib/II ELEVATE trial, an open-label umbrella study. This report focuses on updated safety and preliminary efficacy for elacestrant and capivasertib for patients with estrogen receptor (ER)-positive/HER2-negative advanced breast cancer who experienced disease progression on first-line endocrine therapy plus CDK4/6 inhibition (Abstract 1098). 

Gastroesophageal Cancer
Gastrointestinal Cancer

Elizabeth Smyth, MD, on New Data in Gastric/Gastroesophageal Cancers

Elizabeth Smyth, MD, of Oxford NIHR Biomedical Research Centre, Churchill Hospital, discusses three major studies presented at this year’s meeting: the antibody-drug conjugate izalontamab brengitecan in recurrent or metasatic esophageal squamous cell carcinoma (Abstract 4008); the ATTRACTION-6 study of chemoimmunotherapy in HER2-negative advanced gastric/gastroesophageal junction (GEJ) cancer (Abstract 4006); and an investigational EP4 antagonist in combination with chemoimmunotherapy as a first-line strategy for HER2-negative gastric/GEJ cancer (Abstract 4007). 

 

Bladder Cancer

Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial

Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).

Lung Cancer

Jessica J. Lin, MD, on Neladalkib in Advanced ALK-Positive NSCLC

Jessica J. Lin, MD, Mass General Brigham Cancer Institute, presents data from the ALKOVE-1 study, which is looking at the investigational ALK tyrosine kinase inhibitor (TKI) neladalkib among patients with ALK-positive non–small cell lung cancer (NSCLC); Dr. Lin discusses the first analyses of phase II TKI-pretreated patients and preliminary data in TKI-naive patients (Abstract 8503).

Hepatobiliary Cancer

Daneng Li, MD, on Tegavivint in Advanced HCC

Daneng Li, MD, of City of Hope, discusses dose-finding results from a phase I/II trial of tegavivint, a downstream Wnt/β-catenin inhibitor, in patients with advanced hepatocellular carcinoma (HCC) (Abstract 4015). 

Advertisement

Advertisement




Advertisement